Supercharged GFP Carrier for Avascular Tissue Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Avascular tissues and partially vascularized tissues, such as articular cartilage and intervertebral discs, pose a challenge due to their low cell density and densely packed extracellular matrix, making it difficult to deliver drugs and molecules effectively and sustainably.
Innovation Solution
A carrier system with a cationic charge distribution, such as engineered supercharged green fluorescence protein (GFP), is used to facilitate the delivery of payload molecules to these tissues by linking with a payload molecule and utilizing a linker for sustained release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional delivery systems are used, then the structure is simple, but the delivery efficiency to avascular tissue is poor
Solution Approach 1:
The patent modifies the charge distribution parameter of the carrier by engineering supercharged GFP variants with different net charges (e.g., +9, +15, +25, +36) and surface charge distributions. This parameter change enables the carrier to interact effectively with the negatively charged ECM in avascular tissues, dramatically improving delivery efficiency without requiring complex multi-component structures
Solution Approach 2:
The patent creates carriers with non-uniform surface charge distributions where specific regions have different charge densities. The engineered GFP carriers have localized positive charge clusters on their surfaces that specifically interact with negative charge groups in the ECM, while maintaining overall structural simplicity. This local quality optimization enhances tissue penetration and cellular uptake
2Duration of action of moving object
If sustained delivery is achieved through carrier linkage, then the duration of action is extended, but the device complexity increases
Solution Approach 1:
The patent employs engineered GFP carriers with pre-designed charge distributions and structural features that are optimized before payload attachment. The carriers are pre-characterized for their interaction with avascular tissue, and the linkage chemistry is pre-optimized to ensure controlled release kinetics. This preliminary optimization allows sustained delivery without requiring complex real-time control mechanisms
Solution Approach 2:
The patent uses the engineered GFP carrier as an intermediary between the payload and the avascular tissue. The carrier's specific charge distribution mediates the interaction with the negatively charged ECM, enabling sustained delivery through electrostatic interactions while maintaining a relatively simple overall system architecture compared to complex controlled-release mechanisms
3Productivity
If cationic carriers are used to penetrate negatively charged ECM, then the delivery effectiveness improves, but the risk of clearance increases
Solution Approach 1:
The patent systematically varies the net charge parameter of the GFP carrier (creating variants with +9, +15, +25, and +36 charges) to optimize the balance between ECM penetration and clearance resistance. By tuning this parameter, the carriers achieve effective delivery to avascular tissues while minimizing recognition and clearance by the immune system, thereby improving both delivery effectiveness and reliability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The carrier system enables effective and sustained delivery of payload molecules to avascular and partially vascularized tissues, maintaining therapeutic levels for extended periods, reducing the risk of clearance and minimizing off-target side effects.
Implementation Method 1
the carrier is a cationic carrier and/or has a surface charge distribution such that about 40% or greater of a continuous region of the surface is positively charged
Data Source
AI summary
Provided here in are methods and compositions for delivering a payload molecule to a charged avascular tissue or charged partially vascularized tissue in a subject, the method including administering to a subject in need thereof an effective amount of a carrier, wherein the carrier is a cationic carrier and/or has a surface charge distribution such that about 40% or greater of a continuous region of the surface is positively charged, and wherein the carrier is linked with a payload molecule, to deliver the payload molecule to the charged avascular tissue and/or the charged partially vascularized tissue.